Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
US-11896649-B2 · Feb 13, 2024 · US
US10357464B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10357464-B2 |
| Application number | US-201113183257-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 14, 2011 |
| Priority date | Sep 20, 2006 |
| Publication date | Jul 23, 2019 |
| Grant date | Jul 23, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.
Opening claim text (preview).
What is claimed is: 1. A method for reducing pain perception in a mammalian subject in need of such pain reduction, the method consisting of topically administering to the skin of said subject a topical patch consisting of sevoflurane and one or more pharmaceutically acceptable carriers in an amount effective to reduce pain perception in the subject, wherein the administering does not result in general anesthesia in the subject, and wherein the subject is not under general anesthesia; wherein the topical administration results in analgesia; wherein the volatile anesthetic is the only analgesic agent present in the pharmaceutical preparation in an amount sufficient to reduce pain in said subject; wherein the topical administration is not by inhalation; and wherein said topical administration reduces pain perception in the subject. 2. The method of claim 1 , wherein the method comprises treating chronic pain in the subject. 3. The method of claim 1 , wherein the method comprises treating acute pain in the subject. 4. The method of claim 1 , wherein the pharmaceutical preparation is delivered to anesthetize a portion of said subject prior to a surgery. 5. The method of claim 1 , wherein the administration is periodic. 6. The method of claim 1 , wherein the administration is a one-time event. 7. The method of claim 1 , wherein the volatile anesthetic is periodically administered to the subject on separate occasions. 8. The method of claim 1 , wherein the method results in elimination of pain perception of a portion of the body of the subject. 9. The method of claim 1 , wherein the subject is a human. 10. The method of claim 1 , wherein the subject is a mouse or a rat.
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Centrally acting analgesics, e.g. opioids · CPC title
for peripheral neuropathies · CPC title
Anaesthetics · CPC title
Local anaesthetics · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.